ZYME
Zymeworks Inc

2,437
Mkt Cap
$1.46B
Volume
1.66M
52W High
$19.50
52W Low
$9.03
PE Ratio
-19.69
ZYME Fundamentals
Price
$19.30
Prev Close
$18.47
Open
$18.65
50D MA
$16.36
Beta
0.93
Avg. Volume
589,698.67
EPS (Annual)
-$1.62
P/B
4.35
Rev/Employee
$266,797.20
Loading...
Loading...
News
all
press releases
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 25.73%: Here's is How to Trade
The mean of analysts' price targets for Zymeworks (ZYME) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·13d ago
News Placeholder
More News
News Placeholder
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape Next-Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire VANCOUVER, BC, Oct. 15, 2025 USA News Group...
PR Newswire·14d ago
News Placeholder
Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy?
Does Zymeworks Inc. (ZYME) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·14d ago
News Placeholder
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.
Stocktwits·2mo ago
News Placeholder
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
Zacks·3mo ago
News Placeholder
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.
Zacks·3mo ago
News Placeholder
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zymeworks (ZYME) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·3mo ago
News Placeholder
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of +105.77% and +256.65%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
Zymeworks (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·3mo ago
News Placeholder
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy
Zacks·4mo ago

Latest ZYME News

View

Advertisement|Remove ads.

Advertisement|Remove ads.